Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014 (2014), Article ID 294017, 6 pages
http://dx.doi.org/10.1155/2014/294017
Clinical Study

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China

1Department of Endocrinology and Metabolism, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 1630 Dongfang Road, Shanghai 200127, China
2Department of Endocrinology and Metabolism, Shanghai Gongli Hospital, Shanghai, China

Received 11 December 2013; Revised 18 January 2014; Accepted 27 January 2014; Published 4 March 2014

Academic Editor: Amar Abderrahmani

Copyright © 2014 J. Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Xu, L. Wang, J. He et al., “Prevalence and control of diabetes in Chinese adults,” The Journal of the American Medical Association, vol. 310, pp. 948–959, 2013. View at Google Scholar
  2. Z. Yang, X. Xing, J. Xiao et al., “Prevalence of cardiovascular disease and risk factors in the Chinese population with impaired glucose regulation: the 2007–2008 China national diabetes and metabolic disorders study,” Experimental and Clinical Endocrinology and Diabetes, vol. 121, pp. 372–374, 2013. View at Google Scholar
  3. J. He, D. Gu, X. Wu et al., “Major causes of death among men and women in China,” The New England Journal of Medicine, vol. 353, no. 11, pp. 1124–1134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Bi, D. Zhu, J. Cheng et al., “The status of glycemic control: a cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the jiangsu province of China,” Clinical Therapeutics, vol. 32, no. 5, pp. 973–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Z. Li, L. N. Ji, Z. L. Meng et al., “Management status of type 2 diabetes mellitus in tertiary hospitals in Beijing: gap between guideline and reality,” Chinese Medical Journal, vol. 125, pp. 4185–4189, 2012. View at Google Scholar
  6. L. N. Ji, J. M. Lu, X. H. Guo et al., “Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables,” BMC Public Health, vol. 13, article 602, 2013. View at Google Scholar
  7. H. E. Tamez-Perez, S. L. Proskauer-Pena, M. I. Hernrndez-Coria, and A. J. Garber, “AACE comprehensive diabetes management algorithm 2013,” Endocrine Practice, vol. 19, pp. 736–737, 2013. View at Google Scholar
  8. J. H. B. Scarpello and H. C. S. Howlett, “Metformin therapy and clinical uses,” Diabetes and Vascular Disease Research, vol. 5, no. 3, pp. 157–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. “American Diabetes Association Standards of medical care in diabetes: 2007,” Diabetes Care, vol. 30, pp. S4–S41, 2007.
  10. “American Diabetes Association Standards of Medical Care in Diabetes: 2012,” Diabetes Care, vol. 35, pp. S11–S63, 2012.
  11. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetes Care, vol. 35, pp. 1364–1379, 2012. View at Google Scholar
  12. A. Consoli, R. Gomis, S. Halimi et al., “Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications,” Diabetes and Metabolism, vol. 30, no. 6, pp. 509–516, 2004. View at Google Scholar · View at Scopus
  13. D. M. Nathan, J. B. Buse, M. B. Davidson et al., “Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: aonsensus statement from the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetologia, vol. 52, no. 1, pp. 17–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. Y.-L. An, Y. Gao, Q. Zhu et al., “Features of insulin secretion and insulin resistance in newly diagnosed type 2 diabetes of different body mass indices,” Zhonghua yi xue za zhi, vol. 89, no. 16, pp. 1117–1121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-B. Li, D.-L. Zhu, H.-M. Tian et al., “Characteristics of dysfunction of islet β-cell in newly diagnosed type 2 diabetic patients,” Zhonghua yi xue za zhi, vol. 86, no. 36, pp. 2537–2541, 2006. View at Google Scholar · View at Scopus
  16. American Diabetes A, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 29, supplement 1, pp. S43–S48, 2006. View at Google Scholar
  17. R. Moses, “Fixed combination of repaglinide and metformin in the management of type 2 diabetes,” Diabetes, Metabolic Syndrome and Obesity, vol. 2, pp. 101–109, 2009. View at Google Scholar · View at Scopus
  18. Group UPDS, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. Group UPDS, “Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34),” The Lancet, pp. 854–865, 1998. View at Google Scholar
  20. J. S. Skyler, R. Bergenstal, R. O. Bonow et al., “Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association,” Diabetes Care, vol. 32, pp. 187–192, 2009. View at Google Scholar · View at Scopus
  21. L. Monnier, H. Lapinski, and C. Colette, “Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c,” Diabetes Care, vol. 26, no. 3, pp. 881–885, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Riddle, G. Umpierrez, A. DiGenio, R. Zhou, and J. Rosenstock, “Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes,” Diabetes Care, vol. 34, pp. 2508–2514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. C.-Z. Wu, D. Pei, A.-T. Hsieh et al., “Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide,” Archives of Pharmacal Research, vol. 33, no. 3, pp. 411–416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Fuhlendorff, P. Rorsman, H. Kofod et al., “Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes,” Diabetes, vol. 47, no. 3, pp. 345–351, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Mitrakou, D. Kelley, M. Mokan et al., “Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance,” The New England Journal of Medicine, vol. 326, no. 1, pp. 22–29, 1992. View at Google Scholar · View at Scopus
  26. G. Derosa, A. Mugellini, L. Ciccarelli, G. Crescenzi, and R. Fogari, “Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin,” Diabetes Research and Clinical Practice, vol. 60, no. 3, pp. 161–169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Li, H. Tian, Q. Li et al., “Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in type 2 diabetic patients: a randomized controlled double-blind and double-dummy multicentre clinical trial,” Diabetes, Obesity and Metabolism, vol. 9, no. 4, pp. 558–565, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Zhang, P. Bu, Y.-H. Xie et al., “Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in newly diagnosed type 2 diabetics,” Chinese Medical Journal, vol. 124, no. 2, pp. 172–176, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. Chinese Diabetes Society, “China guideline for type 2 diabetes,” Chinese Journal of Diabetes, vol. 2, supplement 2, pp. 1–56, 2010. View at Google Scholar
  30. L. Ji, H. Li, X. Guo, Y. Li, R. Hu, and Z. Zhu, “Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial,” PLoS ONE, vol. 8, Article ID e57222, 2013. View at Google Scholar